SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?


To: Thomas J Pittman who wrote (5153)12/19/1997 10:17:00 AM
From: aknahow  Read Replies (2) | Respond to of 17367
 
T.J. news hit after the close approval was expected but in tril of about 61 8 showed improved results over 6 with the standard treatment. Chirontreatment was more toxic. Used for treatment of a type of menningitis of the brain caused by hard tumors. Other co was Depo (something). Exact news on Yahoo and all over, above posted from memory and subject to lapses.<g>

Hurts biotechs becauses serves as reminder there are no givens but not related to Xoma menningococcemia trials even as competitor.